Pharscin Pharmaceutical's (SHE:002907) Ganjie Bingmei Tablets completed the domestic drug manufacturing filing process with China's National Medical Products Administration, according to a Shenzhen bourse filing on Wednesday.
The drug is used to treat dry throat, sore throat, hoarseness and pharyngeal mucosal congestion.
The Chinese pharmaceutical company's shares slipped 1% at the close.
Dixon Technologies (India) (NSE:DIXON, BOM:540699) has an average rating of overweight and mean price target of 12,175.57 Indian rupees, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
TCL Electronics (HKG:1070) recorded HK$359 million in attributable profit for the first quarter of 2026, up 124% from HK$161 million a year earlier, according to a Wednesday filing with the Hong Kong bourse.Earnings per share were HK$0.1416, compared with HK$0.0641 in the prior year period.Revenue rose 15% year on year to HK$29.2 billion, figures showed.
Hong Kong stocks edged higher on Wednesday ahead of the meeting between U.S. President Donald Trump and Chinese President Xi Jinping.The Hang Seng Index added 0.2%, or 40.53 points, to close at 26,388.44. The Hang Seng China Enterprises Index barely moved in negative territory to finish at 8,876.38.Trump is expected to arrive in Beijing on Wednesday ahead of talks scheduled for Thursday and Friday.The leaders of the world's two largest economies are set to hold their first face-to-face meeting in more than six months.Discussions are expected to focus on Iran, Taiwan, artificial intelligence, and nuclear weapons, while both sides also weigh extending their critical minerals agreement.Meanwhile, tensions in the Middle East remained unresolved after Trump said he was unlikely to seek China's assistance in ending the conflict with Iran.In corporate news, two companies made their debut on the Hong Kong bourse.Metis TechBio (HKG:7666) closed nearly 127% higher at HK$23.80, well above the offer price of HK$10.50.Impact Therapeutics (HKG:7630) advanced over 108% to close at HK$41.86, compared with the offer price of HK$20.10.